

United States Patent and Trademark Office

_ Ja.

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/647,544	10/26/2000	Evy Lundgren-Akerlund	003300-685 8350	
21839	7590 11/17/2004		EXAMINER	
BURNS DOANE SWECKER & MATHIS L L P POST OFFICE BOX 1404			HADDAD, MAHER M	
	IA, VA 22313-1404	· - ·		PAPER NUMBER
			1644	
			DATE MAILED: 11/17/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Advisory Action	09/647,544	LUNDGREN-AKERLUND, EVY				
, action, riode.	Examiner	Art Unit				
	Maher M. Haddad	1644				
The MAILING DATE of this communication appe	ears on the cover sheet with the	correspondence address				
THE REPLY FILED 14 October 2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.						
PERIOD FOR REPLY [check either a) or b)]						
a) The period for reply expires <u>6</u> months from the mailing date	e of the final rejection.					
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).						
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
1. A Notice of Appeal was filed on 14 October 2004. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.						
2. The proposed amendment(s) will not be entered because:						
(a) ⊠ they raise new issues that would require further consideration and/or search (see NOTE below);						
(b) they raise the issue of new matter (see Note below);						
(c) ☐ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or						
(d) 🔲 they present additional claims without canceling a corresponding number of finally rejected claims.						
NOTE: <u>See Continuation Sheet</u> .						
3. Applicant's reply has overcome the following rejection(s):						
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).						
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for reconsideration has been considered but does NOT place the application in condition for allowance because:						
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.						
7. ☑ For purposes of Appeal, the proposed amendment(s) a) ☑ will not be entered or b) ☐ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.						
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed:						
Claim(s) objected to:						
Claim(s) rejected: <u>1,23-25,76 and 126</u> .						
	Claim(s) withdrawn from consideration: <u>2-21,26-31,33-46,48-75,77-86,88-99,101-108,110-125 and 127-137.</u>					
8. The drawing correction filed on is a) appro						
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)						
10. Other:						
· ·						

Continuation of 2. NOTE: The proposed amendment, filed 10/14/04, to claims 126 and 146, which recites "the integrin subunit alpha10 is a polypeptide to a detectable moiety" raises new issues that would require further consideration and/or search. Claims 126 and 146 are indefinite in the recitation of "the integrin subunit alpha10 is a polypeptide to a detectable moiety". Claims 126 and 142 depends from claims 1 and 142, respectively, claims 1 and 142 recite "a recombinant or isolated collagen binding integrin subunit alpha10 consisting of SEQ ID NO:2/4...". Since the the pharase "consisting of" is close term, it is unclear how the the claimed polypetide would be attached to detectable moiety.he proposed amendment to claims 126 and 146.

SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600